Skip to Main Content

Nathan A. Hasiuk


D   484.270.1498
F   610.667.7056

Nathan A. Hasiuk, a partner of the Firm, concentrates his practice on securities fraud matters. Nathan is an experienced litigator and trial lawyer who represents institutional and individual investors in both class actions and direct actions brought under the federal securities laws. Nathan’s experience includes prosecuting cases from the investigation and complaint drafting stages through all phases of litigation, including motions to dismiss, document, deposition and expert discovery, class certification, summary judgment, pre-trial motions, and appeal.

Nathan’s prior cases resulted in hundreds of millions of dollars in recoveries for clients. These matters include In re Ocwen Fin. Corp. Securities Litigation (S.D. Fla) ($49 million settlement); In re Snap Inc. Securities Litigation, (C.D. Cal.) ($187.5 million settlement); and In re Luckin Coffee Inc. Securities Litigation (S.D.N.Y.) ($175 million settlement).

Nathan is currently representing shareholders in multiple high-profile securities fraud actions, including In re Celgene Corp. Securities Litigation (D.N.J.) and Sjunde AP-Fonden v. The Goldman Sachs Group (S.D.N.Y.).

Prior to joining the Firm, Nathan served as an Assistant Public Defender in Philadelphia, where he successfully represented hundreds of clients in both bench and jury trials.

Nathan is a Phi Beta Kappa honors graduate of Temple University. He received his law degree from the Temple University Beasley School of Law.


Current Cases

  • CASE CAPTION In re Acuity Brands, Inc. Securities Litigation
    COURT United States District Court for the Northern District of Georgia
    CASE NUMBER 1:18-cv-02140-MHC
    JUDGE Honorable Mark H. Cohen
    PLAINTIFF Public Employees’ Retirement System of Mississippi
    DEFENDANTS Acuity Brands, Inc., Vernon J. Nagel, Richard K. Reece, & Mark A. Black
    CLASS PERIOD October 7, 2017 to April 3, 2017, inclusive

    This securities fraud class action arises from Acuity’s false and misleading statements regarding its ability to sustain the growth rate it experienced from 2010 to 2015.

    From 2010 to 2015, Acuity experienced a rapid growth rate fueled by the recovery in non-residential construction following the 2008 financial crisis and a wide transition to LED lighting. Acuity’s relationship with The Home Depot created a strong foundation for its extraordinary sales growth, as the Company experienced nine consecutive quarters of record growth. However, by the middle of 2015, competitive pressures in the lighting industry, including increased competition from overseas suppliers, lower LED prices, and a failure to break into the smart lighting solutions market, as well as a dramatic decline in sales to The Home Depot, slowed the Company’s growth considerably. Acuity’s investors were kept in the dark about all of these fundamental developments while the Defendants materially misrepresented Acuity’s ability to maintain the growth rate that it experienced in the previous five years.

    Acuity’s declining growth rate was revealed to the public gradually when the Company reported three consecutive quarters of below-expectation results. Acuity’s stock prices deteriorated, causing massive losses to shareholders.

    Plaintiff filed a Consolidated Amended Class Action Complaint on behalf of a putative class of investors, alleging that Acuity, Vernon Nagel, and Richard Reece violated Section 10(b) of the Exchange Act by making materially false and misleading statements regarding the growth rate of Acuity; and that Nagel, Reece, and Mark Black as controlling persons of Acuity violated Section 20(a) of the Exchange Act. On August 12, 2019, the United States District Court for the Northern District of Georgia granted in part and denied in part Defendants’ motion to dismiss.

    On August 25, 2020, Plaintiff’s motion for class certification was granted, certifying the following class: “All persons who invested in the publicly traded common stock of Acuity Brands, Inc. between October 7, 2015, through April 3, 2017 (the ‘Class Period’) and were damaged thereby.” The Court appointed Plaintiff, the Public Employees’ Retirement System of Mississippi, as Class Representative; and Kessler Topaz Meltzer & Check and Labaton Sucharow as Class Counsel. 

    On December 2, 2021, Plaintiff filed a motion seeking preliminary approval of a $15.75 million dollar settlement to resolve all claims against Defendants. On December 23, 2021, the District Court granted that motion, and scheduled the final approval hearing for June 3, 2022.

    Read Consolidated Amended Class Action Complaint Here

    Read Order Denying Motion to Dismiss Here

    Read Order Granting Motion for Class Certification Here

  • CASE CAPTION In re Celgene Corporation Securities Litigation
    COURT United States District Court for the District of New Jersey
    CASE NUMBER 2:18-cv-04772-JMV-JBC
    JUDGE Honorable John Michael Vazquez and Honorable James B. Clark, III
    PLAINTIFF AMF Pensionsförsäkring AB (“AMF”)
    DEFENDANTS Celgene Corporation (“Celgene”), Scott A. Smith, Terrie Curran, and Philippe Martin
    CLASS PERIOD April 27, 2017 through April 27, 2018, inclusive

    This securities fraud case involves Celgene’s misrepresentations and omissions about two billion dollar drugs, Otezla and Ozanimod, that Celgene touted as products that would make up for the anticipated revenue drop following the patent expiration of Celgene’s most profitable drug, Revlimid.

    Celgene launched Otezla, a drug treating psoriasis and psoriatic arthritis, in 2014. Celgene primed the market that Otezla sales were poised to sky-rocket, representing that Otezla net product sales would reach $1.5 billion to $2 billion by 2017. Throughout 2015 and 2016, Defendants represented that Celgene was on-track to meet the 2017 sales projection. As early as mid-2016, however, Defendants received explicit internal warnings that the 2017 projection was unattainable, but continued to reaffirm the 2017 target to investors. By October 2017, however, Celgene announced that the Company had slashed the 2017 guidance by more than $250 million and lowered the 2020 Inflammatory & Immunology (“I&I”) guidance by over $1 billion. Celgene’s stock price plummeted on the news.

    Ozanimod, a drug treating multiple sclerosis, is another product in Celgene’s I&I pipeline, and was initially developed by a different company, Receptos. In July 2015, Celgene purchased Receptos for $7.2 billion and projected annual Ozanimod sales of up to $6 billion despite the fact that Ozanimod was not yet approved by the U.S. Food and Drug Administration (“FDA”).

    Celgene told investors that it would file a New Drug Application (“NDA”) for Ozanimod with the FDA in 2017. Unbeknownst to investors, however, Celgene discovered a metabolite named CC112273 (the “Metabolite”) through Phase I testing that Celgene started in October 2016, which triggered the need for extensive testing that was required before the FDA would approve the drug. Despite the need for this additional Metabolite testing that would extend beyond 2017, Defendants continued to represent that Celgene was on track to submit the NDA before the end of 2017 and concealed all information about the Metabolite.  In December 2017, without obtaining the required Metabolite study results, Celgene submitted the Ozanimod NDA to the FDA. Two months later, the FDA rejected the NDA by issuing a rare “refuse to file,” indicating that the FDA “identifie[d] clear and obvious deficiencies” in the NDA.  When the relevant truth was revealed concerning Ozanimod, Celgene’s stock price fell precipitously, damaging investors.   

    On February 27, 2019, AMF filed a 207-page Second Amended Consolidated Class Action Complaint against Celgene and its executives under Section 10(b) of the Securities Exchange Act. On December 19, 2019, U.S. District Judge John Michael Vasquez issued a 49-page opinion sustaining AMF’s claims as to (1) Celgene’s and Curran’s misstatements regarding Otezla being on track to meet Celgene’s 2017 sales projections, and (2) Celgene’s, Martin’s, and Smith’s misstatements about the state of Ozanimod’s testing and prospects for regulatory approval.

    On November 29, 2020, Judge Vasquez certified a class of “All persons and entities who purchased the common stock of Celgene Corp. between April 27, 2017 through and April 27, 2018, and were damaged thereby” and appointed Kessler Topaz Meltzer & Check as Class Counsel. Discovery is ongoing.

    Read Second Amended Consolidated Class Action Complaint Here

    Read Opinion Granting and Denying in Part Motion to Dismiss Here

    Read Opinion Granting Class Certification Here

    Click Here to Read the Class Notice